scispace - formally typeset
G

Gabriel N. Hortobagyi

Researcher at University of Texas MD Anderson Cancer Center

Publications -  1415
Citations -  115570

Gabriel N. Hortobagyi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 166, co-authored 1374 publications receiving 104845 citations. Previous affiliations of Gabriel N. Hortobagyi include University of Texas System & University of Texas Medical Branch.

Papers
More filters
Journal ArticleDOI

Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis

TL;DR: The results suggest that Ki‐67 immunostaining correlates well with nuclear grade and clinical outcome in node‐negative breast carcinoma, and both 5‐year disease‐free and overall survivals were strongly associated with percentage of cells stained with Ki‐ 67 antibody.
Journal ArticleDOI

Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond

TL;DR: Novel cytotoxic therapy strategies include the development of anthracycline, taxane, and oral fluoropyrimidine analogues; antifolates; topoisomerase I inhibitors, and multidrug resistance inhibitors; a better understanding of the biology of breast cancer is providing novel treatment approaches.
Journal ArticleDOI

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

TL;DR: It will be important to characterize mechanisms of resistance in metastatic tumors to determine which novel targeted therapy will be most appropriate for individual patients.
Journal ArticleDOI

Imaging Bone Metastases in Breast Cancer: Techniques and Recommendations for Diagnosis

TL;DR: Recent innovations in bone imaging are discussed and algorithms are presented, based on the strengths and weaknesses of each technique, to facilitate the most successful and cost-effective choice of imaging studies for the detection of osseous metastases.
Journal ArticleDOI

Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer

TL;DR: Higher BMI was associated with worse pCR to neoadjuvant chemotherapy in women with operable breast cancer and its association with worse overall survival suggests that greater attention should be focused on this risk factor to optimize the care of breast cancer patients.